Surrozen SRZN
NASDAQ SRZN
$22.76 +0.22 (+0.98%)
As of: Sep 4, 2026 · 3:59 PM EDT

Surrozen (SRZN) Preferred Stock Liabilities (2020 - 2021)

Surrozen (SRZN) posted quarterly Preferred Stock Liabilities of $78.0 million for Q2 2021, down 4.39% quarter-over-quarter from $81.6 million in Q1 2021.

Analysis

Surrozen (SRZN) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Surrozen's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $78.0 million for Q2 2021.

  • In Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $78.0 million; the TTM figure through Jun 2021 stood at $78.0 million (changed N/A YoY), while the FY2020 annual figure was $81.9 million, changed N/A from the prior year.
  • Preferred Stock Liabilities for Q2 2021 stood at $78.0 million, down from $81.6 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $81.9 million in Q4 2020, with the low at $78.0 million in Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Surrozen 263.35 Mn 263.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 78.04 Mn
Mar 31, 2021 81.63 Mn
Dec 31, 2020 81.86 Mn